31 results about "Anti estrogenic" patented technology

The present invention provides methods for treating and preventing gynecomastia by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with gynecomastia, this reduces the effective estrogen-androgen ratio in the breast tissue, thereby reducing ductal proliferation, epithelial and stromal hyperplasia, and pain. In patients at risk for developing gynecomastia, 4-hydroxy tamoxifen's anti-estrogenic effect prevents tissue proliferation and its accompanying pain.

Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.

The present disclosure provides a compound of Formula I:

or a pharmaceutically acceptable salt wherein X, R¹-R⁸, Y¹-Y⁵, m, n, p, and q are defined herein. The novel 2H-chromene compounds are useful for the modulation of disorders mediated by estrogen, and other disorders, as described herein. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions.

The present invention relates to the treatment of a woman for endometriosis comprising the administration of IFN-gamma, a cytokine antagonist and/or an anti-estrogenic agent.

Syntheses of steroids such as 3-hydroxy-7α-methyl-21-[2′-methoxy-4′-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate (“SR 16234”) and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serves as a starting material or intermediate. The latter compound may be readily prepared from estrone-3-methyl ether. Certain intermediates in these syntheses also have value as therapeutic agents, for example in the treatment of prostate disorders such as prostatic cancer.

The invention discloses novel application of Gypensapogenin B in medicament for treating osteoporosis. Osteoporosis is one of vital diseases which are harmful to human health, and the number of patients with osteoporosis is increased progressively along with aging of population, which brings huge social, medical and economical burden to the whole world. Although home and abroad related experts and scholars pay attention to prevention and treatment of osteoporosis, an effective treatment medicament to the disease does not exist. In vivo tests discover that the Gypensapogenin B has remarkable effect in resisting osteoporosis. Experiment results indicate that the Gypensapogenin B can inhibit strengthening of bone conversion caused by ovariectomized, so that bone is less destroyed, the blood calcium concentration can be improved, and bone deposition are favored. The Gypensapogenin B has treatment effect on osteoporosis caused by anti-estrogenic deficiency, and does not have estrogen-like side effect.

The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.

The invention relates to application of clomifene citrate to anti-mycobacterium tuberculosis medicines. Clomifene citrate has estrogenic and antiestrogenic properties that appear to prevent the release of gonadotropins, follicle-stimulating hormone and luteinizing hormone, thus leading to follicular development and maturation, ovulation and subsequent corpus luteum development and function and then resulting in pregnancy. It is found through researches that the clomifene citrate has an antitubercular effect and has good development value. The application of the clomifene citrate to anti-mycobacterium tuberculosis medicines and the obvious anti-mycobacterium tuberculosis effect of the clomifene citrate are disclosed for the first time.

The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.

The invention discloses a medicine for treating hysteromyoma and a preparation method thereof. The medicine is characterized in that the effective component of the medicine composition is glycyrrhetinic acid. The invention relates to the medicine for treating hysteromyoma and the preparation method thereof. It is creatively found that glycyrrhetinic acid can effectively inhibit hysteromyoma, and specifically, treatment is achieved through the anti-estrogenic function of glycyrrhetinic acid. Other normal tissue and cells are protected to the largest extent while hysteromyoma is inhibited, and side effects of glycyrrhetinic acid are small.

Anti-hormonal (anti-estrogenic steroid) therapy and immunotherapy are used in combination to treat breast cancer. The preferred immunotherapeutic agent is an immunogen, preferably comprising sialyl-Tn, and more preferably is a sialyl-Tn/KLH conjugate.

The invention relates to an application of prawnella in treatment or prevention of osteoporosis. The P.histicola bacteria are used as symbiotic bacteria in normal human intestinal tracts and have excellent safety, animal experiments on estrogen-deficient mice find that the P.histacola can be used for preventing bone mass loss of the mice; the imbalance of intestinal flora caused by estrogen deficiency is regulated, the expression of inflammatory factors is inhibited, the intestinal permeability increase caused by estrogen deficiency is reduced, then inflammatory factors in the intestinal tractwall are reduced, differentiation, maturation and activation of osteoclasts guided by RANKL are inhibited; the P.histacola bacteria have effects of osteoporosis resistance, bone absorption reducing,bone mass loss inhibition and estrogen deficiency osteoporosis resistance, and can meet the requirements of long-term taking, economy, safety and no side effect required by osteoporosis prevention andtreatment as the micro-ecological preparation.

The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1):

in which

• • R₁ represents a hydrogen atom, etc.,
  • R₂ represents a C₁-C₇ halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.